title: Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis.
abstract: Oral ganciclovir has been used as prophylaxis and therapy against cytomegalovirus in patients with HIV infection and following organ transplantation. Oral ganciclovir has clear practical advantages over intravenous ganciclovir but has a relatively low bioavailability and this may be problematic in at-risk patients with malabsorption. The bioavailability and therefore therapeutic potential of oral ganciclovir in cystic fibrosis (CF) patients post-lung transplant (LT) might be expected to be inadequate given the high incidence of malabsorption in these patients. An 8 h pharmacokinetic study was performed in 12 CF patients 160 +/- 122 days post-transplant who had been taking 1 g oral ganciclovir tds for 3 days with food (plus normal enzyme supplements). Mean (range) serum creatinine was 150 Imol/L (70-280). Blood was sampled at 0.5, 1, 2, 3, 4, 6 and 8 h post-final dose. Plasma was stored at -20 degrees C and later analysed by highperformance liquid chromatography. Mean peak concentration (C(max)) was 4.8 mg/L (0. 96-12.8), mean minimum concentration (C(min)) was 3.6 mg/L (0.78-11. 7) and mean area under the curve (AUC) was 35.4 mg.8 h/L (8-99). C(max), C(min) and AUC correlated significantly with one another (P < 0.001) as well as with serum creatinine and creatinine clearance (P < 0.01). When corrected for alterations in renal function, plasma oral ganciclovir levels are as predicted for other transplant populations. Three days of oral ganciclovir results in therapeutically useful plasma drug levels in the CF LT population, despite a background of general malabsorption. C(max), C(min) and AUC are highly correlated, allowing for the possibility of steady-state drug monitoring to confirm that the recommended dosing algorithm produces appropriate plasma levels.
authors.affiliation: Lung and Heart Transplant Service, Departments of Clinical Pharmacology, Pharmacy and Clinical Biochemistry, Alfred Hospital, Prahran 3181, Australia.
authors.forename: G I
authors.initials: GI
authors.lastname: Snell
authors.forename: T C
authors.initials: TC
authors.lastname: Kotsimbos
authors.forename: B J
authors.initials: BJ
authors.lastname: Levvey
authors.forename: M
authors.initials: M
authors.lastname: Skiba
authors.forename: D M
authors.initials: DM
authors.lastname: Rutherford
authors.forename: D C
authors.initials: DC
authors.lastname: Kong
authors.forename: T J
authors.initials: TJ
authors.lastname: Williams
authors.forename: H
authors.initials: H
authors.lastname: Krum
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D003404:Creatinine / Q000097:blood; D003550:Cystic Fibrosis / Q000378:metabolism* / Q000601:surgery*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D016040:Lung Transplantation / Q000502:physiology*; D008297:Male
chemical_list: D000998:Antiviral Agents; D003404:Creatinine; D015774:Ganciclovir